NCT00553813View on ClinicalTrials.gov

A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

April 30, 2010

Conditions
Pancreatic Cancer
Interventions
DRUG

TPI 287

Intravenous dose of 125 mg/m2 TPI 287 on Day 1, Day 8, and Day 15 in a repeating 28 day cycle.

Trial Locations (4)

20817

Center for Cancer and Blood Disorders, Bethesda

28250

Hospital Madrid, Madrid

92270

Desert Hematology Oncology Medical Group, Inc., Rancho Mirage

21231-1000

Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins University, Baltimore

Sponsors
All Listed Sponsors
lead

Cortice Biosciences, Inc.

INDUSTRY

NCT00553813 - A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter